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Abstract
Background: Water utilities continue to be interested in implementing syndromic surveillance for the enhanced
detection of waterborne disease outbreaks. The authors evaluated the ability of sales of over-the-counter diarrheal
remedies available from the National Retail Data Monitor to predict endemic and epidemic gastrointestinal disease
in the San Francisco Bay Area.
Methods: Time series models were fit to weekly diarrheal remedy sales and diarrheal illness case counts. Cross-
correlations between the pre-whitened residual series were calculated. Diarrheal remedy sales model residuals were
regressed on the number of weekly outbreaks and outbreak-associated cases. Diarrheal remedy sales models were
used to auto-forecast one week-ahead sales. The sensitivity and specificity of signals, generated by observed
diarrheal remedy sales exceeding the upper 95% forecast confidence interval, in predicting weekly outbreaks were
calculated.
Results: No significant correlations were identified between weekly diarrheal remedy sales and diarrhea illness case
counts, outbreak counts, or the number of outbreak-associated cases. Signals generated by forecasting with the
diarrheal remedy sales model did not coincide with outbreak weeks more reliably than signals chosen randomly.
Conclusions: This work does not support the implementation of syndromic surveillance for gastrointestinal disease
with data available though the National Retail Data Monitor.
Background
Syndromic surveillance has received much attention as a
method for health departments to accelerate the detec-
tion of, the reaction to, or the confirmation of disease
outbreaks [1,2]. After the publication of reports suggest-
ing that monitoring over-the-counter drug sales might
have given advance notice of the 1993 outbreak of cryp-
tosporidiosis in Milwaukee [3-5], federal agencies began
to make explicit recommendations that water utilities
and health departments consider implementing over-
the-counter syndromic surveillance for enhanced water-
borne outbreak detection [6-8]. However, the ability of
over-the-counter syndromic surveillance to enhance the
detection of waterborne disease outbreaks has not been
adequately demonstrated [9].
In the San Francisco Bay Area, drinking water is pro-
vided by the San Francisco Public Utilities Commission
(SFPUC) to 2.4 million customers in four counties. Sup-
ported by the SFPUC, the San Francisco Department of
Public Health’s Water Epidemiology Program maintains
regional, distribution system-wide cryptosporidiosis sur-
veillance. To clarify the validity and representativeness
of sales of over-the-counter diarrheal remedies available
through the National Retail Data Monitor (NRDM) for
prospective outbreak detection, we sought to determine
if these data are related to known outbreaks of infec-
tious gastrointestinal illness in the drinking water service
area [10].
Methods
County and state agencies receive reports of individual
gastrointestinal cases as well as infectious disease out-
breaks. Title 17 of the California Code of Regulations
mandates case reporting of specified diagnosed diseases
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departments by health care providers [11]. Health
departments may also become aware of outbreaks
through follow-up with individual reported cases, citizen
complaints and other modes. The definition of an out-
break differs by disease but typically entails a group of
related cases for which a common source is identified or
suspected; outbreaks may include as few as two cases.
Reports of cases of gastrointestinal disease from 2001-
2007 among residents were requested from each of the
county health departments in the drinking water service
area. Data were transmitted in electronic formats from
three adjacent counties. Reports for each case included
etiology, date of report to the health department, gen-
der, age, city and county.
Electronic records of outbreak data for all three parti-
cipating counties were provided by the California
Department of Public Health which receives outbreak
reports following county and state health department
outbreak investigations. These data were combined and
reconciled with electronic records and records which
were manually extracted from paper files from two of
the participating county health departments. For each
outbreak, information on etiology, number of cases, date
of symptoms onset for the first and last cases, affected
counties, and whether the outbreak occurred in an insti-
tutional setting such as a nursing home was provided.
O u t b r e a k so fr e p o r t a b l ed i s e a s e sa sw e l la so u t b r e a k so f
diseases that are not reportable as listed in Title 17
were included. Individual cases reportable under Title
17 associated with any outbreak may be included in the
diarrhea case dataset; however, sufficient information
was not available to link the outbreak and case datasets.
The Committee on Human Research at the University
of California, San Francisco approved the study
protocol.
Over-the-counter drug sales records were purchased
from the NRDM [10]. Records for the years 2005-2007
were provided as an electronic file. Records for years
2003-2004 were downloaded using the NRDM web
interface. NRDM over-the-counter drug sales records
are divided into 18 categories based on common use,
form and whether intended for adult or pediatric popu-
lations. NRDM drug categories are: diarrhea remedies,
anti-fever adult, anti-fever pediatric, bronchial remedies,
baby/child electrolytes, chest rubs, cold relief adult
liquid, cold relief adult tablet, cold relief pediatric liquid,
cold relief pediatric tablet, cough syrup adult liquid,
cough adult tablet, cough syrup pediatric liquid, cough/
cold, hydrocortisones, nasal product internal, throat
lozenges, and thermometers. Sales are based on the
number of units sold regardless of the package size.
Daily total sales are available for both all units sold by
category and units sold by category excluding units for
which discounts or other promotions were offered dur-
ing the reporting period. NRDM provides information
on the number of stores enrolled and reporting; from
2005 through 2007 approximately 47% of the stores
enrolled to report anti-diarrhea drug sales actually
reported (number of stores enrolled per week: 1389
-1706; number of stores reporting: 592-836).
Our analysis variable was the proportion of non-pro-
motional diarrhea remedy sales to sales of non-promo-
tional drugs for all categories combined (Diarrheal
Remedy Sales). Diarrheal remedies are products taken
for the relief of diarrhea and include bismuth, attapul-
gite, subsalicylate, and loperaminde hydrochloride pro-
ducts. Sales records of diarrheal remedies were available
for the entire study area from July 2003 through 2007.
Proportion sales were used instead of counts to control
for unknown confounders such as changes in store
hours.
Diarrheal Remedy Sales, and gastrointestinal case and
outbreak data were aggregated by week for analysis.
Diarrheal Remedy Sales were aggregated by week of
sale, cases by week of report to the health department
and outbreaks by week of onset of first outbreak-asso-
ciated case. Data were divided into three parts for
model building, model validation, and forecasting.
We used methods developed by Box and Jenkins to
build autoregressive integrated moving average
(ARIMA) models [12]. Estimates of model parameters
were obtained through the method of least squares. All
analyses were performed using SAS version 9.1 (SAS
Institute Inc., Cary, NC, USA). Using Proc ARIMA, fol-
lowing either pre-whitening or double pre-whitening,
Diarrheal Remedy Sales were cross correlated with the
number of diarrhea cases in the same week and with
weekly counts lagged one to 19 weeks before and after.
The relationship between Diarrheal Remedy Sales and
gastrointestinal outbreaks was examined graphically and
through regression. Because a 2006 report by Edge and
colleagues [13] suggested that over-the-counter drug
sales are sensitive to viral infection, specifically Noro-
virus, Diarrheal Remedy Sales were compared to out-
breaks of all etiologies combined and to outbreaks of
Norovirus alone. Furthermore, as institutionalized popu-
lations, such as those in a nursing home, may not pur-
chase drugs from over-the-counter drug vendors in the
same way as the non-institutionalized population, ana-
lyses were repeated excluding outbreaks that occurred
in an institutional setting. Diarrheal Remedy Sales uni-
variate model residuals were regressed on the number
of outbreaks and on outbreak-associated cases per week.
The univariate Diarrheal Remedy Sales ARIMA model
was used to auto-forecast sales for 105 weeks with
weekly model updating (one week ahead forecasting).
Signals were generated when actual observations
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week was any week when one or more outbreaks started
that week or prior to that week but ended that week or
later. Model sensitivity was calculated as the number of
outbreak weeks with a signal divided by the total num-
ber of outbreak weeks. Specificity was calculated as the
total number of weeks without a signal and no detected
outbreaks divided by the total number of weeks without
an outbreak. Calculations were done with all outbreaks
and repeated in subsets of only larger outbreaks with 50
or more or 100 or more cases. To evaluate if model
derived alerts identified outbreak weeks more reliably
than randomly chosen alerts, sensitivity and specificity
calculations were repeated for three sets of randomly
chosen dates.
Results
D i a r r h e a lc a s ed a t aw e r ef i tw i t haf i r s to r d e ra u t o r e g r e s -
sive model and Diarrheal Remedy Sales with an inte-
grated first order moving average model (Case ARIMA
(1,0,0): parameter estimate 0.33, T-ratio 3.09; Diarrheal
Remedy Sales ARIMA(0,1,1): 0.4, 4.42). Figure 1 presents
time series plots of the outbreak -associated gastrointest-
inal cases, individual gastrointestinal cases, Diarrheal
Remedy Sales and differenced Diarrheal Remedy Sales.
From July 2003 through December 2007, there were
233 gastrointestinal outbreaks (Table 1). Most reported
outbreaks were caused by Norovirus or by an unknown
etiology of which many were suspected of being Noro-
virus. More Norovirus outbreaks were reported in each
of 2006 and 2007 than previous years. Norovirus out-
breaks were also larger than outbreaks of other diseases
with a mean number of outbreak-associated cases of 30.
The largest outbreak was of Norovirus at 153 cases.
Thirty percent of outbreaks occurred in an institutional
setting.
In the forecasting period, January 1, 2006 to January 1,
2008, there were 154 outbreaks; 20 with 50 or more,
three of these with 100 or more cases. Table 2 lists
details for outbreaks with 50 or more cases. Table 1
provides the number and size of outbreaks by study
period.
From 2004 through 2007 there were 11,536 reported
gastrointestinal cases. The majority of cases were of
campylobacteriosis, cryptosporidiosis, salmonellosis,
giardiasis, shigellosis and amoebiasis (Table 1). More
cases were reported among children under 5 than for
any other age group; incidence of gastrointestinal illness
was similar across other ages. Sixty-one percent of cases
were male. Although we collected case data from 2001
through 2007, there were abrupt changes in reporting at
the start of 2004; review of the average number of cases
reported by day of the week and year showed consistent
lower overall reporting by day for 2004 through 2007 as
compared to earlier data potentially indicating a change
in surveillance protocols. As these county level changes
persisted in aggregated regional data, the data were
restricted to 2004 and later for analysis.
From July 2003 through December 2007, the propor-
tion of diarrheal remedy sales to total drug sales ranged
from 0.016 to 0.083 with an average of 0.044 and stan-
dard deviation of 0.014. Sales of diarrhea remedies ran-
ged from 1216 to 3512 unit sales per week with an
average of 2435 and standard deviation 441.
No significant correlation at any lag was found
between Diarrheal Remedy Sales and diarrheal cases
(Figure 2). Furthermore, regression analysis of the Diar-
rheal Remedy Sales univariate model residuals did not
reveal an association between the weekly number of
outbreaks or outbreak-associated cases and Diarrheal
Remedy Sales when all outbreaks data were included or
when restricted to Norovirus and/or non-institutional
outbreaks.
Four signals were generated by the Diarrheal Remedy
Sales model (on the weeks of 6/11/06, 1/29/06, 10/15/
06 and 6/10/07). Four of the 20 outbreaks with 50 or
more and one of three with 100 or more cases started
during or lasted through a week with a signal. The two
o u t b r e a k sw i t h1 0 0o rm o r ec a s e sw i t h o u ts i g n a l sw e r e
both non-institutional Norovirus outbreaks with steep
epidemic curves. Sensitivity for all outbreaks and for
outbreaks with 50 or more or 100 or more cases was
low and specificity high (Table 3). The sensitivity and
specificity of the model was identical to a random
selection of three sets of four signals, further support-
ing the conclusion that any relationship between Diar-
rheal Remedy Sales and gastrointestinal illness is
spurious.
Discussion
NRDM Diarrheal Remedy Sales did not predict out-
breaks of gastrointestinal disease or correlate with indi-
vidual cases of diarrheal illness. Signals generated by the
Diarrheal Remedy Sales model did not coincide with
outbreak weeks more reliably than signals chosen
randomly.
To generate Diarrheal Remedy Sales signals we
employed ARIMA modeling and forecasting. Time series
modeling, including ARIMA, has a long history of use in
econometrics and statistical quality control [14,15].
More recently it has been adopted by public health
practitioners to model subjects such as influenza and
hospital admissions, weather and suicides, and gun bans
and homicides [16-18]. Time series modeling accounts
for autocorrelation, trend and seasonality which when
present in data can cause ordinary regression techniques
to present spurious variance estimates and incorrect
inference.
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Page 3 of 9Figure 1 Plots of Outbreak-Associated Gastrointestinal Cases, Individual Gastrointestinal Cases, Diarrheal Remedy Sales, and
Differenced Diarrheal Remedy Sales. Standardized weekly counts of gastrointestinal outbreak-associated cases, diarrheal illness case reports,
Diarrheal Remedy Sales and differenced Diarrheal Remedy Sales in three San Francisco Bay Area Counties from January 2004 to July 2005. All
data aggregated to the first Sunday of week. Diarrheal Remedy Sales are aggregated by week of sale, cases by week of report to the health
department and outbreak cases by week of onset of the first associated case. Vertical axes are measured in standard deviations.
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Page 4 of 9Over-The-Counter Anti-Diarrheal Drug Sales and
Surveillance:
In the aftermath of the 1993 Milwaukee waterborne
cryptosporidiosis outbreak in which thousands were
sickened it was reported that sales of over-the-counter
anti-diarrheal and anti-cramping drugs at one phar-
macy increased by a factor of 17 to 20 as compared to
the same period in the previous year [3]. This finding,
supported by similar anecdotal reports stimulated the
push for the implementation of waterborne disease
surveillance with over-the-counter drug sales [19].
However, a later review of the feasibility and timeliness
of surveillance data available during that outbreak–
water treatment plant effluent turbidity logs, clinical
laboratory diagnosis, nursing home diarrhea rates, hos-
pital emergency room logs, random digit dialing tele-
phone surveys, water utility complaint logs, school
absentee logs and sales of anti-diarrhea drugs–revealed
a poor response rate by pharmacies and a lack of time-
liness [5].
A subsequent retrospective analysis of anti-nauseants
and anti-diarrhea drug sales during waterborne out-
breaks of cryptosporidiosis (Battlefords, Saskatchewan),
and E. coli 0157:H7 infection and campylobacteriosis
(Walkerton, Ontario), found that increased over-the-
counter drug sales coincided with or lagged shortly
behind illness onset [4]. The authors concluded that
over-the-counter drug sales trends would provide a
more timely and sensitive tool than monitoring hospital
emergency department visits or traditional passive
laboratory based surveillance. Nonetheless, over-the-
counter drug sales data limitations were noted: data
from only one of three pharmacies in Battlefords and
one of six in Walkerton were available and formatted
appropriately for analysis.
Studies of the seasonality of over-the-counter drug
sales and diarrhea illness have also contributed evidence
supporting over-the-counter drug sales for enhanced
gastrointestinal surveillance. In an unidentified Canadian
providence, sales of anti-nauseant and anti-diarrhea
Table 1 Gastrointestinal Outbreak and Case Characteristics in the San Francisco Bay Area, July 2003 through
December 2007
N Outbreak-Associated Cases* N
Maximum Median Mean
All Disease Outbreaks 233 153 19 25 Case Etiology
Outbreaks of Reportable Diseases 31 65 12 16 campylobacteriosis 3316
Outbreaks of Not-Reportable Diseases 202 153 21 27 cryptosporidiosis 2210
Study Period salmonellosis 2187
Model (6/29/03 to 7/2/05)† 71 110 15 23 giardiasis 1739
Validation (7/3/05 to 12/31/05) 11 26 14 13 shigellosis 1002
Forecasting (1/1/06 to 12/30/07) 154 153 21 27 amoebiasis 512
Outbreak Etiology hepatitis A 152
norovirus 144 153 24 30 Escherichia coli infection 151
unknown 41 80 18 21 vibriosis 118
salmonellosis 17 65 13 22 typhoid 62
Bacillus cereus /Clostridium
perfringens infection
8 38 8 12 listeriosis 39
Escherichia coli infection 4 18 11 11 yersiniosis 26
scombroid poisoning 3 7 5 5 legionellosis 17
bacterial toxin poisoning 3 22 4 10 ciguatera poisoning 5
chemical toxin poisoning 2 4 3 3
vibriosis 2 27 21 21
ciguatera poisoning 2 3 3 3
hepatitis A 1 2 2 2
trichinosis 1 2 2 2
cryptosporidiosis 1 16 16 16
yersiniosis 1 1 1 1
giardiasis 1 14 14 14
rotavirus 1 6 6 6
campylobacter 1 3 3 3
*Number of cases not available for five outbreaks (3 salmonellosis, 2 norovirus) between January 1, 2006 and January 1, 2008.
† Modeling period was shorter –Jan 4, 2004 to Jul 2, 2005– for Univariate Case Modeling and Cross Correlation Analysis.
s Outbreak and case data sets are not mutually exclusive or encompassing.
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Page 5 of 9Table 2 Gastrointestinal Outbreaks with 50 or More Cases in the San Francisco Bay Area, January 2006 through
December 2007
Etiology Cases First Onset Last Onset Institutional Over-the-Counter Drug ARIMA (0,1,1) Signal
Norovirus 101 1/25/06 Yes Yes
Unknown/Norovirus 60 4/18/06 No Yes
Unknown/Norovirus 62 4/24/06 Yes Yes
Norovirus 107 4/25/06 5/2/2006 No No
Unknown/Norovirus 55 4/26/06 No/Unknown Yes
Norovirus 50 5/8/06 Yes Yes
Norovirus 81 10/26/06 Yes No
Norovirus 86 11/23/06 Yes No
Norovirus 72 11/30/06 Yes No
Norovirus 63 11/30/06 Yes No
Unknown 80 12/7/06 Yes No
Unknown 61 12/7/06 No/Unknown No
Norovirus 76 1/3/07 Yes No
Norovirus 60 1/8/07 Yes No
Norovirus 92 7/13/07 7/17/07 No No
Norovirus 153 8/3/07 8/17/07 No/Unknown No
Norovirus 51 9/15/07 9/19/07 No/Unknown No
Norovirus 52 12/20/07 1/1/08 Yes No
Norovirus 52 12/22/07 Yes No
Norovirus 76 12/22/07 1/15/08 No/Unknown No
Abbreviations: ARIMA(0,1,1) First Order Integrated Moving Average
Figure 2 Cross Correlations Between Diarrheal Remedy Sales and Diarrheal Illnesses. Diarrheal Remedy Sales and diarrheal illness case
reports cross correlations at time lags from zero to 19 weeks. No significant correlations, bars exceeding the 95% confidence interval (shaded),
were found.
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Page 6 of 9over-the-counter drugs from one major retailer with 19
locations, accounting for only 12% of all pharmacies in
the region, had similar seasonal temporality with
reported Norovirus infections [13]. However, over-the-
counter drug sales did not coincide with diarrhea due to
other etiologies specifically bacterial or parasitic which
are more prevalent during summer months. Similarly,
electrolyte sales followed the same seasonal pattern as
hospitalizations for selected pediatric diarrheal illness
(Rotavirus and intestinal infections due to organisms
not elsewhere classified (ICD9 008.61)) when combined
with pediatric respiratory illnesses (Pneumonia, bronch-
opneumonia, influenza, bronchiolitis, respiratory syncy-
tial virus) [20]. This study included very few diarrhea
illness etiologies and the number of cases of each illness
are not presented; the incidence of respiratory illnesses,
especially seasonal influenza, is likely to greatly exceed
that of diarrheal illnesses therefore obscuring the rela-
tionship between over-the-counter drug sales and diar-
rhea illness. The authors acknowledged that it is not
possible to rule out a coincidental relationship which is
driven by other phenomena.
Local and state health departments have implemented
syndromic surveillance systems with over-the-counter
anti-diarrhea drug sales monitoring components but few
retrospective studies and no successful reports from
ongoing surveillance projects are published [3,21,22].
Only one report, now antiquated, presents the progress
of a functioning over-the-counter anti-diarrhea drug
sales monitoring program. Similar to our results, Das et
al (2005) reported that they had found no consistent
relationship between over-the-counter anti-diarrhea
drug sales and emergency department visits for gastroin-
testinal illness in New York City [22]. And, despite
its availability nationwide for more than six years,
no publications evaluate surveillance with NRDM over--
the-counter diarrheal remedy drug sales in practice. One
retrospective study presented graphs demonstrating the
similar temporality of analgesic, anti-fever, anti-diarrhea
and cough, and cold drugs combined and calls to the
poison control center in 2003 [23]. Although our
literature review did identify a number of reports sug-
gesting that syndromic surveillance with over-the-coun-
ter anti-diarrheal drug sales could enhance traditional
disease control activities, the widespread adoption of
syndromic surveillance systems and the paucity of pub-
lished reports on over-the-counter drug sales monitor-
ing systems, and NRDM specifically, suggest publication
bias may be present.
Limitations
Our study had several limitations. First, there were no
large regional outbreaks in our dataset and the high data
variability of diarrhea remedy sales may make it difficult
to discern changes resultant from relatively small
increases in illness. Although we do not believe that indi-
vidual early health seeking behavior such as over-the-
counter drug purchases would be different when an indi-
vidual’s illness is part of an undetected larger outbreak,
in a large outbreak the number of people pursuing over-
the-counter remedies might produce a signal that is sig-
nificantly above the noise in the baseline.
Over-the-counter drug sales records as provided by
the NRDM have several limitations. The usability of
these data could be improved if participation by enrolled
stores was increased or if meta-information on partici-
pating stores such as market coverage and on the drugs
included in each category were made available. While
we did not find any association between gastrointestinal
disease and purchases of diarrheal remedies in general,
it is possible that one product or a subset of products
included in this category might have coincided with
known disease. Furthermore, our study was not able to
assess whether improvements in over-the-counter drug
sales reporting systems might enhance the performance
of this type of syndromic surveillance. The use of over-
the-counter drugs sales for surveillance may be prohibi-
tive due to the cost and logistics of data collection, or
the proprietary and secret nature of the data [3].
County-by-county differences in disease reporting, and
aggregations of diseases with varying severities may have
masked finding a true association. These aggregations
Table 3 Sensitivity and Specificity of Diarrheal Remedy Sales Model-Generated and Randomly Selected Signals
All Outbreaks Outbreaks with ≥ 50 Cases Outbreaks with ≥ 100 Cases
Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
Over-the-counter drug IMA(1) Signal
(6/11/06, 1/29/06, 10/15/06, 6/10/07)*
4% (4/94) 100% (11/11) 4% (1/26) 97% (76/79) 14% (1/7) 97% (95/98)
Random Signals 1
(1/29/06, 6/11/06, 9/9/07, 2/18/07)*
4% (4/94) 100% (11/11) 8% (2/26) 97% (77/79) 14% (1/7) 97% (95/98)
Random Signals 2
(2/12/06, 7/9/06, 12/3/06, 9/23/07)*
3% (3/94) 91% (10/11) 4% (1/26) 97% (76/79) 0% (0/7) 96% (94/98)
Random Signals 3
(5/21/06, 1/3/07, 9/16/07, 12/9/07)*
3% (3/94) 100%(11/11) 4% (1/26) 97% (77/79) 0% (0/7) 97% (95/98)
* First day of week for each model generated and randomly generated signal.
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Sales fluctuations resultant from isolated outbreaks. We
therefore cannot rule out that county specific syndromic
surveillance may be more sensitive than the region-wide
surveillance examined in this analysis.
While studies show that over-the-counter drugs are
the first option for many, health seeking behavior varies
by factors including age, gender and culture [24-32].
One study examined healthcare-seeking behavior in
response to diarrheal illness specifically. This survey of
351 adults reporting acute gastroenteritis (diarrhea,
vomiting or both) found significant differences between
those who use over-the-counter drugs and those who do
not [24]. Although care should be exercised in applying
these findings from Canada to the US as each have dis-
tinct health care systems, the lack of correlation that we
found in our study between Diarrheal Remedy Sales and
diarrheal cases could indicate that these data sources
measure the occurrence of diarrhea in different popula-
tions. Similarly, high population mobility may increase
the chances that Diarrheal Remedy Sales and cases are
not both included in the region of study and that
dispersed outbreaks may not be detected [33].
Conclusions
This study did not support the implementation of syn-
dromic surveillance with National Retail Data Monitor
Diarrheal Remedy Sales for enhanced gastrointestinal
outbreak detection of waterborne or other origins. How-
ever, we cannot exclude the possibility that NRDM data
maybe useful for detecting larger outbreaks.
A secondary finding of the study was of the increasing
role of Norovirus in disease outbreaks in our region.
From 2004 through 2006 approximately 56% of all out-
breaks were due to Norovirus infection, 15% of these
occurred in institutional settings. In 2007 the proportion
attributable to Norovirus rose to 73%; 65% of outbreaks
in 2007 were institutional. The increased incidence of
outbreaks due to Norovirus may be attributable to
enhanced detection or reporting; however, similar
increases were noted in North Carolina, New York and
Wisconsin [34]. Especially given the proven effectiveness
of existing programs [35], public health departments
must carefully evaluate the efficacy and added worth of
surveillance systems to avoid the possibility that
increased funding for programs such as syndromic sur-
veillance are not accompanied by cutbacks in funding
for programs such as institutional Norovirus prevention,
resulting in a net increase in overall morbidity [36].
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